TLDR: Viva Biotech has received the prestigious 2025 APAC Technology Innovation Leadership Recognition from Frost & Sullivan for its groundbreaking advancements in integrated intelligent drug discovery. The award acknowledges the company’s pioneering AI-driven platforms that significantly accelerate drug development timelines, reduce costs, and broaden therapeutic innovation within the global pharmaceutical R&D landscape.
Shanghai, China – September 29, 2025 – Viva Biotech, a leading integrated drug discovery platform, today announced it has been awarded Frost & Sullivan’s 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry. This esteemed accolade highlights Viva Biotech’s exceptional contributions to revolutionizing preclinical research and development through its advanced AI-driven platforms. The recognition underscores the company’s consistent leadership in seamlessly integrating artificial intelligence (AI) with robust laboratory-driven validation, thereby reshaping the future of drug discovery and fostering scalable innovation in a highly competitive market.
Frost & Sullivan’s rigorous benchmarking process, which evaluates companies across critical dimensions such as strategy effectiveness and execution, saw Viva Biotech emerge as a standout performer. The company demonstrated a remarkable ability to align cutting-edge technologies with evolving client demands, delivering precision and efficiency at scale.
Priyanka Jain, Senior Research Analyst at Frost & Sullivan, lauded Viva Biotech’s innovative approach, stating, “By integrating multimodal artificial intelligence with extensive wet lab validation, Viva Biotech has established one of the most versatile discovery platforms in the industry. Its ability to support diverse modalities—from small molecules and antibodies to emerging therapies such as PROTACs, molecular glues, and RNA-targeting compounds—significantly reduces development timelines and costs for global clients.”
Innovation remains at the core of Viva Biotech’s operational philosophy. The company’s proprietary AI-Driven Drug Discovery (AIDD) platform, which includes modules like V-Scepter, V-Orb, and V-Mantle, is specifically designed to tackle long-standing challenges in drug design through a combination of predictive modeling and physics-based simulations.
Dr. Derek Ren, CEO of Viva Biotech (Shanghai) Ltd., expressed his gratitude for the recognition. “We are very honored to receive this award from Frost & Sullivan,” said Dr. Ren. “This recognition validates our vision of building a truly integrated platform that unites AI-driven drug discovery (AIDD) with structure-based drug design (SBDD). The company’s AI platform is transforming the once-impossible into achievable breakthroughs. In future, we will continue to accelerate the pace of AI-driven drug discovery and development and lead in a new era of scientific innovation.”
Also Read:
- Indegene Digital Summit 2025: Pioneering AI’s Role in Life Sciences Commercialization
- Vietnam’s AI Prowess Recognized at Prestigious AI Awards 2025
This award reaffirms Viva Biotech’s unwavering commitment to enhancing client experience and solidifying its global standing as a pioneer in intelligent drug discovery.
